EGFR and non-small cell lung carcinoma: For NSCLC with driver gene mutations/translocations, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, and c-ros oncogene 1 (ROS1) genes, the first-line therapy with tyrosine kinase inhibitors (TKIs) targeting gene mutation/translocation is recommended.